Tenapanor
Sodium-Hydrogen Exchanger 3 Inhibitor — ALIMENTARY TRACT AND METABOLISM
Also known as: AZD-1722, AZD1722, AZD1722-hydrochloride, ibsrela, KHK-7791, RDX-5791, RDX5791, tenapanor hydrochloride
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Tenapanor is an onp drug in the Sodium-Hydrogen Exchanger 3 Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2019. Its mechanism of action is classified as Organic Anion Transporting Polypeptide 2B1 Inhibitors and Sodium-Hydrogen Exchanger 3 Inhibitors. DrugCentral lists 2 molecular targets, including SLC9A3 and Slc9a3. Recorded indications include Chronic kidney disease and Irritable bowel syndrome characterized by constipation.
- Approval status: onp (first approved 2019 by the FDA).
- Drug class: Sodium-Hydrogen Exchanger 3 Inhibitor.
- Mechanism of action: Organic Anion Transporting Polypeptide 2B1 Inhibitors; Sodium-Hydrogen Exchanger 3 Inhibitors.
- Molecular targets: SLC9A3 and Slc9a3 (2 listed in DrugCentral).
- Indications: Chronic kidney disease and Irritable bowel syndrome characterized by constipation.
- ATC code: A06AX08 (Other drugs for constipation).
- Molecular formula: C50H66Cl4N8O10S2; molecular weight 1145.04 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Chronic kidney disease
- Irritable bowel syndrome characterized by constipation
Contraindications (1)
- Gastrointestinal obstruction
Mechanism & targets
| Mechanism of action (MoA) | Organic Anion Transporting Polypeptide 2B1 Inhibitors; Sodium-Hydrogen Exchanger 3 Inhibitors |
|---|---|
| Established pharmacologic class | Sodium-Hydrogen Exchanger 3 Inhibitor |
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Sodium/hydrogen exchanger 3 | SLC9A3 | inhibitor | IC50 9.06 |
| Sodium/hydrogen exchanger 3 | Slc9a3 | unknown | IC50 8.20 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2019-09-12 | FDA | — | ARDELYX INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A06AX08 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Other drugs for constipation |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Diarrhoea | 1957.2 |
| Hospitalisation | 338.9 |
| Death | 253.0 |
| Inappropriate schedule of product administration | 186.7 |
| Treatment noncompliance | 100.8 |
| Therapy interrupted | 86.7 |
| Insurance issue | 80.0 |
| No adverse event | 72.7 |
| Wrong technique in product usage process | 57.3 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Tenapanor is on its molecule page.
| Molecular formula | C50H66Cl4N8O10S2 |
|---|---|
| Molecular weight | 1145.04 g/mol |
| CAS number | 1234423-95-0 |
| InChIKey | DNHPDWGIXIMXSA-CXNSMIOJSA-N |
| PubChem CID | 71587953 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Tenapanor used for?
DrugCentral lists the following indications for Tenapanor: Chronic kidney disease and Irritable bowel syndrome characterized by constipation.
How does Tenapanor work?
Tenapanor is classified as Organic Anion Transporting Polypeptide 2B1 Inhibitors and Sodium-Hydrogen Exchanger 3 Inhibitors; its molecular targets in DrugCentral include SLC9A3 (inhibitor) and Slc9a3.
When was Tenapanor first approved?
Tenapanor was first approved by the FDA in 2019.
What drug class does Tenapanor belong to?
Tenapanor is in the Sodium-Hydrogen Exchanger 3 Inhibitor class.
What is the chemical formula of Tenapanor?
Tenapanor has the molecular formula C50H66Cl4N8O10S2 and a molecular weight of 1145.04 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5349 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3301627 — compound record and bioactivity
- PubChem CID 71587953 — chemical identifiers
- DrugBank DB11761 — drug record
- FDA UNII WYD79216A6 — substance identity
- DailyMed: FDA labels for Tenapanor — current prescribing information (label search)
- UniProt P48764 (SLC9A3) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.